From the Rocky Mountain Poison and Drug Center, Denver Health Authority, Denver, Colo (Drs Dart and Bogdan); University of Colorado Health Sciences Center, Denver (Dr Dart); Department of Emergency Medicine, Kino Community Hospital, Tucson, Ariz (Dr Seifert); Department of Pediatrics, University of Arizona, Tucson (Dr Boyer); Division of Medical Toxicology, University of California–San Diego Medical Center and the San Diego Division of the California Poison Control System (Dr Clark); Department of Surgery, John D. Archbold Memorial Hospital, Thomasville, Ga (Dr Hall); Department of EmergencyMedicine and the New Mexico Poison Center, University of New Mexico Health Sciences Center, Albuquerque (Dr McKinney); Arizona Poison and Drug Information Center, School of Pharmacy, University of Arizona, Tucson (Mr McNally); Department of Medicine, Veterans Affairs Hospital, Gainesville, Fla (Dr Kitchens); Department of Medical Toxicology, Good Samaritan Regional Medical Center, Phoenix, Ariz, and Division of Clinical Medicine, University of Arizona College of Medicine, Tucson (Dr Curry); and Therapeutic Antibodies Inc, Nashville, Tenn (Drs Ward and Porter).
Current therapy for crotaline snakebite includes antivenin (Crotalidae) polyvalent, an antivenom with numerous adverse effects. We compared the efficacy and safety of 2 dosing regimens with a new antivenom, Crotalinae polyvalent immune Fab (Fab AV).
A single dose of Fab AV alone (as-needed [PRN] group) was compared with an initial dose plus repeated treatments during 18 hours (scheduled group) in a multicenter randomized trial. The study included patients with minimal or moderate envenomation by a crotaline snake within the preceding 6 hours, aged 10 years or older, in whom worsening of the envenomation syndrome was observed before Fab AV treatment. After treatment with Fab AV to achieve initial control, patients were randomized to the scheduled or PRN treatment group. Scheduled group patients received additional doses of Fab AV every 6 hours for 3 doses. The PRN group received no planned additional doses of antivenom.
The mean severity score of the 31 patients decreased from 4.35 to 2.39 points (P<.001); there was no difference between scheduled and PRN groups. No patient in the scheduled group received unplanned Fab AV doses, but 8 of 16 patients in the PRN group received unplanned doses (P = .002). Acute reactions occurred in 6 patients (19%), and serum sickness occurred in 6 (23%) of 26 patients who returned for follow-up.
In the first randomized trial of antivenom in the United States, Fab AV effectively terminated venom effects. Since the unplanned use of Fab AV in the PRN group was common, the treatment regimen may require more than 1 initial dose.
VENOMOUS snakebite is an important health problem. Several thousand victims suffer snakebite each year in the United States.1 There are approximately 6 deaths per year from snakebite.2 In addition, 15% to 40% of patients develop long-term sequelae of envenomation ranging from minor limb disfigurement to death.3
In the United States, rattlesnakes, water moccasins, and copperhead snakes cause nearly all medically important snakebites. Currently, the therapy for snakebite is limited to general supportive care of local tissue injury, coagulopathy, and hypotension as well as the administration of antivenom to selected patients. The only antivenom available in the United States is antivenin (Crotalidae) polyvalent (Wyeth-Ayerst Laboratories, Philadelphia, Pa), a hyperimmune horse serum product that neutralizes many components of crotaline snake venom. Although effective, its use has been limited by the frequency of adverse effects. Acute reactions occur in 20% to 25% of patients; the severity of reaction ranges from minor rashes to life-threatening anaphylaxis.4- 6 Death caused by overwhelming acute bronchospasm and hypotension has occurred. Equally troublesome is the frequent occurrence of serum sickness, a delayed type III hypersensitivity reaction that occurs in 50% to 75% of patients treated with the Wyeth-Ayerst Laboratories product.4,7 Serum sickness may cause fever, diffuse rash, intense urticaria, arthralgia, hematuria, and constitutional symptoms that persist for several days and often prevent normal activities unless treated with antihistamines and systemic administration of corticosteroids.
A new medication has been developed for the treatment of crotaline snakebite. Crotalinae polyvalent immune Fab (ovine) (Therapeutic Antibodies Inc, Nashville, Tenn) is produced in a manner similar to digoxin immune Fab (Digibind; Glaxo Wellcome Inc, Research Triangle Park, NC). Individual flocks of sheep are immunized with 1 of 4 crotaline venoms (Western diamondback, Eastern diamondback, and Mojave rattlesnakes and the cottonmouth). The immune serum from each flock is digested with papain to produce antibody fragments (Fab), which are then purified by chromatographic methods to remove the immunogenic Fc portion of the antibody and the nonneutralizing components of ovine serum. The 4 monospecific antivenoms thereby produced are combined to form the final antivenom product. The new antivenom averaged 5.2 times (range, 3.0-11.7 times) more potent than antivenin (Crotalidae) polyvalent on the basis of weight in a mouse lethality model.8 A prospective open-label trial of the new antivenom in 11 patients found that all patients improved after treatment and no acute or delayed allergic reactions occurred.9 However, progression of limb swelling was found in 3 patients, with time of onset ranging from 6 to 19 hours. To suppress local recurrence, an improved dosing schedule was devised. The purpose of this study was to compare the efficacy and safety of Crotalinae polyvalent immune Fab (Fab AV) with the use of 2 dosing regimens. We believe this to be the first randomized trial of antivenom in North America.
Inclusion criteria were (1) minimal or moderate envenomation (defined herein) by a North American crotaline snake within the 6 hours preceding administration of the study drug, (2) age 10 years or older, and (3) progression of the envenomation syndrome. Progression was defined as worsening under direct observation of an evaluation measure used in grading the envenomation: local injury, coagulation abnormality, or systemic symptoms or signs.
Minimal envenomation was defined as swelling, pain, and ecchymosis limited to the immediate bite site; no systemic symptoms and signs; and normal coagulation measures with no clinical evidence of bleeding. Moderate envenomation was defined as swelling, pain, and ecchymosis involving less than 1 extremity (if on the trunk, head, or neck, extending less than 50 cm); systemic symptoms and signs may be present but not life-threatening (may include but are not limited to nausea, vomiting, oral paresthesia or unusual tastes, mild hypotension [systolic blood pressure >90 mm Hg], mild tachycardia [heart rate <150 beats per minute], and tachypnea); and coagulation measures may be abnormal, but without clinical evidence of bleeding (minor hematuria, gum bleeding, and nosebleeds are allowed if not deemed severe by the investigator).
Exclusion criteria were (1) lack of progression of the envenomation, (2) severe venom poisoning (swelling, pain, and ecchymosis involving more than an entire extremity or threatening the airway; markedly abnormal systemic symptoms and signs, including severe alteration of mental status, severe hypotension, severe tachycardia, tachypnea, or respiratory insufficiency; and abnormal coagulation measures with serious bleeding or severe threat of bleeding), (3) bite by the copperhead snake (Agkistrodon contortrix), (4) infusion of more than 1 vial of antivenin (Crotalidae) polyvalent before enrollment, (5) history of hypersensitivity to a sheep-derived product, (6) use of corticosteroids or any experimental medication in the 4 weeks preceding study enrollment, (7) pregnancy or lactation, (8) previous enrollment in the study, (9) inability to give informed consent, or (10) the presence of any disease that would interfere with patient examination.
This study was a prospective, randomized, controlled, open-label comparative trial (Figure 1) performed at 7 sites (Table 1). The study was performed between June 11, 1994, and November 1, 1996. Written informed consent was obtained and the study was approved by the institutional review board at each site. After enrollment and standardized initial assessment (history, physical examination, and laboratory tests), each patient received an intravenous dose of 6 or 12 vials of Fab AV to achieve initial control. Initial control of the envenomation syndrome was prospectively defined as cessation of progression of all components of envenomation: local effects, systemic effects, and coagulopathy. This included complete termination of swelling progression and complete reversal of systemic effects. Coagulopathy had to return to normal or near-normal values. Because the study was not blinded, patients were randomized to a treatment group only after initial control was achieved to distribute evenly any bias in the investigator's assessment of when initial control had been achieved. Randomization was assigned individually by means of a predetermined randomization procedure administered by a central call center.
Schematic diagram of study. PRN indicates as needed.
Treatment with Fab AV was administered in 2 phases. First, a dose of 6 vials was administered to obtain initial control. If necessary, a second dose of 6 vials was allowed to achieve initial control. If initial control could not be achieved with 12 vials of Fab AV and within 6 hours of initial treatment, treatment was deemed to have failed.
After initial control was achieved, patients were randomized to the as-needed (PRN) or scheduled group for the second phase. The second phase involved clinical monitoring for progression or resolution of venom effect. Patients in the PRN group received no further Fab AV unless the investigator detected progression of one of the signs of envenomation: local effects, systemic effects, or coagulopathy. Additional Fab AV could then be administered without limit in 2-vial increments. Patients in the scheduled group received 2 vials of Fab AV every 6 hours for a total of 3 doses (18 hours) and could receive additional doses if the investigator detected worsening of the envenomation. The severity score was determined at 1, 6, and 12 hours after the establishment of initial control. Swelling measurements were performed every 2 hours from 6 to 12 hours and then every 12 hours until 36 hours after initial control. Safety evaluations, including laboratory tests, were performed at 1, 2, 6, 12, 24, and 96 hours and at 14 days. All patients were discharged within 36 hours.
Each vial of lyophilized Crotalinae polyvalent immune Fab (ovine) contained 750 mg of Fab and sodium phosphate buffer. The Fab preparation has been described previously.8 Each vial was prepared for infusion by reconstitution in 10 mL of sterile water. The initial dose of 6 vials was diluted in normal saline to a final volume of 250 mL and infused during 60 minutes. Two-vial doses were administered during 30 to 60 minutes.
To assess efficacy, each patient was examined at baseline, on achievement of initial control, and at 1, 6, and 12 hours after initial control was achieved. Initial control was defined as the cessation of worsening of all evaluation measures as assessed by the investigator. The primary assessment tool was the snakebite severity score, a previously tested measure that quantifies the clinical effects of venom.10 A secondary measure, the investigator's clinical assessment, was used to confirm the severity score and ascertain its clinical relevance. To perform each assessment, the investigator assigned the patient's response to 1 of 4 categories: (1) clinical response: pretreatment signs and symptoms associated with the bite improved or progression was arrested after treatment with antivenom; (2) partial response: pretreatment signs and symptoms associated with the bite site worsened, but at a slower rate than anticipated; (3) clinical nonresponse: the patient's condition was not favorably affected by the administration of study drug; or (4) not evaluable.
Evaluations for acute hypersensitivity reactions were performed by the investigator at baseline, during study drug administration, and 1, 2, 6, and 12 hours after initial control. An acute reaction was defined broadly as any apparent adverse response that occurred during or within 2 hours of Fab AV infusion. Evaluations for delayed hypersensitivity reactions (serum sickness) were performed at 2, 4, 7, and 14 days after discharge from the hospital. Delayed reactions were defined as any adverse event involving 1 of the following: cutaneous eruption, arthralgia, gastrointestinal tract complaints, or lymphadenopathy occurring more than 24 hours after antivenom administration. In addition, each patient completed a diary for recording of symptoms that occurred between visits.
Sample size calculations were calculated using data from a pilot study.9 A sample size of 28 patients was calculated to achieve 80% power to detect a severity score difference of 1.0 point between groups, assuming an α level of .05 and using 2-sided independent-group t test. A 5% dropout rate was postulated, producing a planned study size of 30 patients.
The primary assessment of efficacy was the snakebite severity score.10 Efficacy was defined as a stable or decreasing severity score during the 12-hour evaluation period after establishment of initial control. Because of the discrete nature of the data, severity scores were compared nonparametrically over time by means of the Friedman test. Severity scores between the 2 dosing regimens were compared at each time point by means of the 2-sided Mann-Whitney test. The 6 components of the severity score were also compared over time by the Friedman test. Statistical significance was defined as a probability less than 5% (P<.05). All tests were performed with commercially available statistical software (Arcus Quickstat Biomedical Version 6.2; Longman Software, Cambridge, England). The proportion of patients in each regimen who developed local swelling or coagulopathy recurrence was compared by Fisher exact test. The total number of vials used in each dosing regimen was compared by a 2-tailed unpaired t test. Safety was assessed by means of descriptive statistics and individual case analysis and review.
There were 31 patients enrolled (Figure 1). No patients were excluded or dropped from the study. The study groups were similar in age, weight, sex and racial composition, initial severity score, range of severity scores, and the amount of Fab AV required to achieve initial control of the envenomation (Table 1). Progression of local swelling was present in all patients before treatment.
All patients were included in the efficacy evaluation. Initial control of the envenomation syndrome was achieved in all patients. The mean total severity score began to decrease on the infusion of Fab AV in all patients and continued to decrease in both groups through the evaluation period (Table 2). The mean severity score of the 31 patients decreased from 4.35 to 2.39 points (P<.001); there was no statistical difference between the scheduled and PRN groups. The decrease in the severity of illness after Fab AV infusion, as represented by the severity score, was composed entirely of reductions in the coagulation, central nervous system, gastrointestinal tract, cardiac, and pulmonary components (data not shown). The local wound component did not decrease or increase after treatment. There were also no differences in the individual component scores between the PRN and scheduled groups. At the follow-up visits, local venom effects were described as improved throughout the study period.
Investigators also categorized the time needed to reconstitute Fab AV into 4 categories (0-10, >10-20, >20-30, or >30 minutes). Overall, for 27 of the patients, 6 (22%) took 0 to 10 minutes for reconstitution, 13 (48%) took greater than 10 to 20 minutes, and 8 (30%) took greater than 20 to 30 minutes; the time was not recorded for 4 patients.
Recurrence was defined as the return of any venom effect after that abnormality had resolved. Thus, return of progression of swelling after its initial arrest had been documented was described as a local recurrence, while return of thrombocytopenia, hypofibrinogenemia, prolongation of prothrombin time, or elevation of levels of fibrin split products was described as a coagulopathy recurrence. The issue of coagulopathy has been addressed in detail previously.11
The planned dose of Fab AV in the scheduled group was a total of 12 to 18 vials (6 or 12 vials for initial control and then 2 vials every 6 hours for 3 doses). The dose in the PRN group was 6 to 12 vials with no planned doses after initial control. As a safety precaution, the protocol allowed the investigator to administer additional "rescue" doses of Fab AV to patients in either group if clinically needed. No patient in the scheduled group received additional Fab AV, while 8 patients (50%) in the PRN group received additional doses for recurrence of local wound progression during the first 12 hours (P = .002; Table 3). Despite the use of different dosing regimens, the total amount of study drug administered was not statistically different between groups: a mean (± SD) total of 13.0 ± 3.9 vials was used in the scheduled group, while 11.1 ± 4.5 vials were used in the PRN group. Each episode of local recurrence was successfully terminated with 2 additional vials of Fab AV. There were no recurrences of local effects after discharge from the hospital.
Six patients (19%) developed an acute reaction during Fab AV infusion; 3 occurred in each study group (Table 4). As categorized by the investigator, there were 4 mild cases of transient urticaria. There were 2 moderate cases: 1 in a patient who developed wheezing and dyspnea and 1 in a patient who developed cough and urticaria. Two patients received no treatment, and all other patients responded promptly to treatment.
Five patients did not return for the 14-day visit. Of the remaining 26 patients, 6 (23%) developed serum sickness (Table 5). Two cases were rated as mild, 2 were moderate, and 2 were severe. The worst case of serum sickness involved diffuse hives and urticaria, which was treated successfully on an outpatient basis with antihistamines and a short course of prednisone. There were no reported sequelae of serum sickness at the 28-day follow-up visit. Notably, the first 5 patients who developed serum sickness were treated with a batch of Fab AV that was later found to contain excess Fc fragments retained from a flawed step in the manufacturing process. A new purification step was introduced, and only 1 (6%) of the subsequent 16 patients developed serum sickness. In contrast, the rate of acute reactions was similar among batches of Fab AV.
The Fab AV was administered concomitantly with opioid, minor analgesic, antiemetic, and anxiolytic medications in nearly all patients (90%). No drug-drug or drug-disease interactions were reported. Preexisting patient conditions included hypertension in 3 patients, hypothyroidism in 2 patients, and renal insufficiency, diabetes, congestive heart failure and hypertension in 1 patient. A total of 3 patients with a history of asthma were enrolled; 2 developed an early reaction during Fab AV infusion.
Crotaline snakebite is a dynamic disease process. By definition, a crotaline envenomation begins with minimal clinical effects (fang marks and perhaps localized pain and swelling). In many cases, however, the initial minimal injury worsens to threaten limb or life. Every envenomation that is destined to become severe must therefore progress through the grades of minimal and moderate. In untreated cases, death has occurred within hours from shock and multiple-organ injury. Conversely, the venom effects may worsen in an indolent manner during many hours or may fail to worsen at all, if no venom was actually injected (the "dry bite"). The variable nature of venomous snakebite renders clinical evaluation difficult. If therapy is applied to a bite that is not destined to worsen, it may erroneously appear to be an effective treatment, while a massive envenomation could overwhelm all forms of therapy, causing an otherwise effective therapy to appear ineffective.
To address these difficulties, we used a comparative trial design with inclusion criteria designed to maximize the probability that the patient had suffered a clinically important envenomation. Patients were enrolled within 6 hours of envenomation, while they still had minimal or moderate grade envenomations and evidence of clinical worsening at the time of antivenom administration. Patients with severe envenomation were excluded because extensive injury may obscure antivenom effect. For example, if the maximal amount of swelling has already occurred, then the antivenom would be expected to have minimal clinical effect.
The primary limitation of this study is the open label design. We attempted to minimize this effect by using a randomized design and a validated severity score with specific definitions to limit and distribute investigator bias. However, the potential bias of open-label studies may manifest in forms for which we could not compensate. Another limitation is the exclusion of patients with severe envenomation, which was desired by the regulatory agency. While an antivenom effective in less severe cases would also be expected to be useful in severe envenomations, further evaluation in this patient group is needed.
Crotalinae polyvalent immune Fab (ovine) successfully achieved initial control of the envenomation syndrome in all study patients, and both groups continued to improve during the 12-hour evaluation period. As judged by the snakebite severity score, the 2 treatment strategies (PRN vs scheduled) showed similar effectiveness. However, additional unscheduled doses to recover control of recurrent local swelling were administered to one half of patients in the PRN group, while no patient in the scheduled group required unplanned doses. This increased the actual total dose administered to the PRN group and caused the 2 groups to receive similar total amounts of antivenom, despite the fact that the dosing regimen for the scheduled group required a minimum dose of 12 to 18 vials while the PRN group required only 6 to 12 vials. This result indicates that repeated doses of Fab AV will likely be needed to provide adequate clinical treatment of envenomation.
The effect of Fab antivenom was most noticeable in the components of the severity score involving the coagulation system, central nervous system, gastrointestinal tract, and cardiovascular system. Each of these measures decreased during the initial infusion of Fab AV and continued to decrease throughout the evaluation period. Thus, venom-induced dysfunction in these areas appears to be a dynamic process that can be terminated and reversed by antivenom. In contrast, the local injury component of the score did not improve. This observation may be explained by the fact that ecchymosis and edema formation involve hemorrhage, cell swelling, and cell death, processes that are less reversible or only slowly reversible.12 It is important that the snakebite severity score did not worsen. Because we did not include an untreated control group, it is impossible to assert that the severity scores of these patients would have worsened. However, an increase in the score would be the expected course for patients who met the inclusion criteria for this study.
This study alters understanding of crotaline snakebite in other ways as well. As noted above, local manifestations recurred in 8 of 16 patients. While this was easily managed by the administration of additional Fab AV, this phenomenon has not been described previously. A related finding is much more striking. In addition to recurrence of local effects, return of coagulation abnormalities was noted in many patients who exhibited a coagulopathy at presentation. Although the information has not entered the mainstream medical literature, anecdotal evidence of this phenomenon has been reported sporadically for nearly 20 years.13 A retrospective analysis of a large database of crotaline snake envenomations indicates that the phenomenon also occurs after the use of the currently available antivenom, antivenin (Crotalidae) polyvalent.14
The pathophysiology underlying either local or coagulopathy recurrence is unknown. However, there are at least 4 potential explanations. First, the snake may have injected sufficient venom to overwhelm the neutralization capacity of the antivenom. A related concept involves the half-life of the antivenom; the elimination half-life of ovine Fab is relatively short for an antibody, 12 to 30 hours.15- 17 Perhaps all venom in the blood was neutralized initially, but continued to be absorbed from the bite site. Unbound Fab AV would be eliminated renally. As the antivenom was eliminated, the point would be reached where further venom absorbed from the bite site could not be neutralized by the unbound Fab AV remaining in the blood. Renewed venom effect could then occur.
Second, it is possible that the venom–Fab AV complex dissociated, allowing the venom injury to redevelop. The antigen-antibody complex in snake venom poisoning may be predisposed to this phenomenon. Many of the venom components have molecular weights of 20 000 to 150 000 daltons. When bound to a Fab with a molecular weight of 50 000 daltons, the complex would be too large for renal excretion, and persistence in the circulation would be expected. A similar phenomenon of recurrence has been documented with digoxin immune Fab, where recurrence of free (unbound) digoxin levels has been documented as early as 12 to 24 hours after administration.18 Because of the high affinity of digoxin immune Fab for digoxin, however, it has been concluded that the cause is much more likely to be redistribution of digoxin.18
Third, the composition of venom components absorbed from the bite site may change over time. Since crotaline snake venom has dozens of components, perhaps those that are absorbed later differ from components absorbed earlier and are not bound as well by antivenom. The components with delayed absorption might then produce effects that could not be terminated by antivenom administration. This explanation seems unlikely because the recurrent coagulopathy caused the same abnormalities as the original coagulopathy and was successfully treated with additional doses of antivenom in most of the patients with recurrence.
Fourth, human antisheep antibodies may have developed. If the patient rapidly produced antibodies against the ovine Fab, these antibodies might have interfered with the binding of Fab to venom components. This is not likely because recurrence occurred within hours to days, and this type of response requires 7 to 19 days to develop.19
We believe the most likely explanation is that venom continues to be absorbed from the bite site for days after injection. Animal and clinical data support this conclusion.17,20,21 The recurrence of venom effect, therefore, should be responsive to further antivenom administration. This was the case in all patients with local recurrence and nearly all patients with coagulopathy recurrence.
Finally, the reconstitution profile for the new antivenom may be clinically important. The antivenom currently available, antivenin (Crotalidae) polyvalent, requires at least 30 to 60 minutes to enter solution. This can become a serious clinical problem when swelling occurs in critical areas such as the airway or the patient manifests systemic effects such as hypotension. An antivenom that could be administered within 15 to 30 minutes would be desirable under these conditions.
The administration of Crotalinae polyvalent immune Fab (ovine) was consistently associated with prompt improvement in the patient's condition. Antivenom dosage was contingent on an individual patient's response. On the basis of our data, the recommended initial dose is 6 vials, with further 6-vial doses until initial control of the envenomation syndrome has been achieved. After initial control has been established, additional 2-vial doses every 6 hours for 3 doses may be needed. Additional 2-vial doses may be needed on the basis of close follow-up for late recurrences of coagulopathy, especially if these effects were present during hospitalization.
Accepted for publication March 13, 2001.
This research was supported by a grant from Protherics Inc, formerly Therapeutic Antibodies Inc.
Corresponding author and reprints: Richard C. Dart, MD, PhD, Rocky Mountain Poison and Drug Center, 1010 Yosemite Cir, Denver, CO 80230 (e-mail: email@example.com).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 86
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.